RGEN
RGEN
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
1
$2.46M
Total Volume
$2.46M
1 transactions
Net Activity
$2.46M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
RGEN has an insider buy conviction of 0%, compared to the Unknown sector buy average of 50%.
Loeillot Olivier
CEO
$2.46M total
Over the last 90 days, corporate insiders at RGEN (RGEN) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 1 were sales. The total volume of insider trading reached $2.46M.
The net insider activity for RGEN shows a net selling bias of $2.46M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Loeillot Olivier (CEO), who traded 12.9K shares valued at $2.46M on Sep 24, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering RGEN and the Unknown sector.
Evaluating a16z Web3 Spinoffs: Insider Activity in Tech Convergence Stocks
Andreessen Horowitz has backed dozens of Web3 startups that later went public. This report tracks board-member Form 4 activity at a16z-affiliated tech convergence companies to identify post-IPO insider conviction signals.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Why Directors Buy Stock in Regional Banks vs. Systemic Banks
Regional bank directors show a much higher propensity for open-market stock purchases than their megabank counterparts. This report explores the governance, ownership structure, and information environment reasons for this divergence, and whether the regional director signal holds predictive value.
FAQs About RGEN Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for RGEN.